Psychedelics Could Revolutionize Couples Therapy
Time, March 14, 2023
“MDMA can build trust, release tension and fear, and erode inhibitions, allowing partners to have hard conversations with compassion and without judgment, says Catherine Auman, a California psychotherapist who coaches clients on how to integrate psychedelics into their lives.”
This psychoactive plant could save lives—and everyone wants to cash in
National Geographic, March 8, 2023
Iboga plants smuggled out of Gabon provide most of the world’s ibogaine, a drug that can help heal trauma and addiction. As the plant enters fair trade, officials hope regulation ensures equity and sustainability.
Australia will allow prescription MDMA and magic mushrooms for some people with mental illness
ABC News USA, March 5, 2023
Australian regulators announced in February that psychiatrists will be able to prescribe psilocybin and MDMA as medication for certain mental health conditions starting July 1 of this year. The move makes Australia the first nation to approve the legal use of MDMA and psilocybin.
Australia is about to legalise MDMA and psilocybin for medicinal use. So how will it work?
ABC News, March 3, 2023
Just three months out from the legalisation of psychedelic medicines for mental health treatment, questions remain among experts about exactly how the drugs will be administered.
Does the ‘hype’ on psychedelics match the reality when it comes to mental health?
News.com.au, February 27, 2023
It sounds crazy doesn’t it? Psychedelic drugs to treat a variety of debilitating mental illness.
But could they be the latest answer to Australia’s spiralling mental health crisis?
The Promise and Perils of Psychedelics
The New England Journal of Medicine, February 23, 2023
In this episode of “Intention to Treat,” a study participant and a long-time investigator of hallucinogenic drugs for psychiatric conditions illuminate the effects of psilocybin in patients with depression.
The Veterans Fighting to Legalize Psychedelics
The New York Times, February 22, 2023
In a major shift that would modify laws set half a decade ago, states and cities around the United States are moving to legalize psychedelics for use as a medical treatment.
The sudden change of heart has a lot to do with who is asking for the substances.
MEPs urge European regulators to move faster on psychedelics
Psychedelic Health, February 21, 2023
Australia’s recent rescheduling of psilocybin and MDMA is inspiring action across the globe.
A group of Members of the European Parliament have sent two letters calling on regulators to move faster on psychedelic healthcare in Europe, stating that “stagnation is creating a disadvantage for millions of Europeans affected by mental health conditions and substance use disorders”.
Psychedelics might change mental healthcare. Will investors follow?
CNBC International, February 17, 2023
Global sales of antidepressant drugs are expected to exceed $20 billion by 2030. Now, some investors are betting that psychedelic therapies can grab a share of that enormous market.
Is it finally time to change the law around magic mushrooms?
Evening Standard, February 16, 2023
Anew digital billboard campaign has appeared around London in the past few days, asking one striking question: Could magic mushrooms be medicine?
Everyone seems to be on psychedelics except me
The Telegraph, January 29, 2023
Read the full PDF here.
Australia’s biggest research trial using psychedelics to treat depression to commence in 2023
Swinburne University, January 25, 2023
Swinburne has signed a $5 million clinical trial research agreement with Woke Pharmaceuticals to embark on Australia’s biggest research trial examining the promise of the active ingredient in psychedelic mushrooms, called ‘psilocybin’, in tackling treatment-resistant depression.
Rapid and durable response demonstrated in the first placebo-controlled study exploring a short-duration psychedelic for depression
Psychiatric Times, January 25, 2023
Small Pharma, a European psychedelic medicine company announced the results of its Phase 2a clinical trial, treating moderate to severe Major Depressive Disorder (MDD) with DMT-assisted therapy. The trial carries special significance, as it is the first-ever clinical trial attempting to treat a mental health disorder with DMT, the shorter-acting chemical cousin to psilocybin.
Scientists are beginning to unravel the effects of psilocybin mushrooms on bipolar disorder
Psypost, January 21, 2023
Scientists are beginning to unravel the effects of psilocybin mushrooms on bipolar disorder. Research of late has shown psilocybin to improve symptoms of depression, which is particularly burdensome to the quality of life for people with bipolar disorder.
Australia the world’s psychedelic research capital as Ingenu studies psilocybin and MDMA
The Australian, January 10, 2023
Australia is emerging as a leading centre for psychedelic medicine trials.
In Pursuit of Altered States of Consciousness
Herald, January 7, 2023
The highs, the lows and the new “normal”, in Pursuit of Altered States of Consciousness. Dive into this intricate article, journeying the spectrum of humanity’s psychedelic experiences and stories.
MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
PR Newswire, January 5, 2023
If approved, MAPS PBC’s MDMA-assisted therapy could be the first psychedelic-assisted therapy used to treat a mental health condition.
What Happens in a Clinical Trial for Psychedelics?
ABC Sydney, January 5, 2023
Josh Szeps from ABC Sydney speaks to Michael Taylor about his experience as a volunteer part of a clinical trial at the Turner Institute for Brain and Mental Health at Monash University.
New York Lawmakers Introduce Psychedelics Legalization Bill
Forbes, January 4, 2023
A trio of New York state lawmakers has introduced a bill to legalize natural psychedelics, including DMT, ibogaine, mescaline, psilocybin and psilocin.
‘Melding with the MRI machine’: The volunteers taking psychedelic drugs for science
Sydney Morning Herald, January 2, 2023
Michael Taylor was lying in an MRI machine when he had the most joyous experience of his life. He is one of 60 volunteers participating in PsiConnect, the first psychedelic trial in Australia involving healthy participants.